We sought to assess whether global longitudinal strain (GLS) measured early during treatment with anthracyclines (at a cumulative dose of 150 mg/m 2 ) can predict subsequent alterations in left ventricular ejection fraction. 
Introduction
Anthracycline therapy is well known for its adverse cardiac effects. [1] [2] [3] Anthracycline-induced cardiotoxicity (AIC) is associated with a poor prognosis. 4 As classic heart failure treatment can potentially reverse cardiac dysfunction at the early stage of cardiac toxicity, 5 timely detection of AIC is crucial. Transthoracic echocardiography is recommended for monitoring left ventricular function in patients receiving anthracyclines. In routine practice, left ventricular systolic function is assessed primarily by the left ventricular ejection fraction (LVEF), measured by twodimensional echocardiography imaging. However, LVEF depends on operator experience and is not sufficiently sensitive to detect subclinical myocardial dysfunction. 6, 7 To overcome these limitations, two-dimensional speckle-tracking imaging has been proposed. This technique allows for a study of global and regional myocardial deformation, especially the longitudinal component, which appears to be the most sensitive. of potentially cardiotoxic drugs, [8] [9] [10] and even after only low to moderate doses of anthracyclines. 11 A recent expert consensus paper strongly recommends GLS assessment for the detection of subclinical left ventricular dysfunction due to anthracycline therapy. 12 Although there is growing evidence that GLS can predict subsequent alterations in LVEF, few data exist on the optimal timing to perform echocardiography. We hypothesized that very early measurement of GLS in the time course of anthracycline therapy could predict subsequent left ventricular systolic dysfunction. The aim of our study was therefore to determine whether assessment of GLS after 150 mg/m 2 of anthracyclines can predict AIC.
Methods

Study population
This was a single-centre, prospective cohort study. Eligibility requirements at screening were the following: patients with lymphoma or leukaemia, requiring anthracycline therapy; age >18 years; and baseline LVEF > 50%. Exclusion criteria were moderate to severe aortic or mitral valve disease; pregnant or breastfeeding women; atrial fibrillation; very poor image quality, defined as two or more inadequately visualized myocardial segments (17-segment model); and an unstable cardiac condition such as pericardial effusion or acute coronary syndrome. The patients were evaluated at four time points: visit 1 (V1), before the initiation of anthracycline therapy; visit 2 (V2), after reaching a cumulative dose of 150 mg/m 2 ; visit 3 (V3), at the end of the treatment; and visit 4 (V4), 1 year after V1. Patients underwent a clinical examination at each visit and standard echocardiography was performed. All patients provided written informed consent. The study was approved by our ethics committee (EudraCT number 2011-002721-22).
Two-dimensional echocardiography
Echocardiography examinations were performed using a Vivid E9 imaging device (GE Medical systems, Horten, Norway). The left ventricular enddiastolic and end-systolic volumes were measured from the apical twoand four-chamber views; LVEF was calculated using Simpson's rule.
GLS was computed from high frame rate (>50 frames/s) apical views (four, two, and three chambers). By tracing the endocardial borders on an end-systolic frame, myocardial speckles were automatically tracked on the subsequent frames. Adequate tracking was verified and was manually corrected if necessary. GLS was obtained as the average of regional strains. Percentage change in GLS (DGLS) and absolute reduction in GLS (abGLS) were calculated between baseline and V2. Other classic diastolic and systolic parameters were recorded according to current guidelines. 13, 14 Digital loops were stored for off-line analysis. For LVEF and GLS, digital loops were done in triplicate to assess inter-and intraobserver variability. LVEF and GLS were analysed by two readers (R.C.-D. and C.C.). The readers were blinded to each other's measurements and to the patient visit number.
Echocardiographic definition of AIC
According to a recent consensus paper, 12 anthracycline cardiotoxicity is defined as a decrease in the LVEF of >10 percentage points, to a value <53%, at V4. This decrease had to be confirmed by a repeat echocardiography performed a few weeks after V4.
Statistical analysis
Data are presented as median [interquartile range] (minimum; maximum) for quantitative variables and count (percentage) for qualitative variables. Baseline characteristics of patients and evolution of echographic variables between V1 and V2 were compared according to the development of cardiotoxicity using either the Wilcoxon rank sum test or Fisher's exact test. The discriminative ability of GLS at baseline and at V2, abGLS, DGLS, and LVEF at V2 were assessed by plotting receiver-operatingcharacteristic (ROC) curves and computing the area under the ROC curve along with its bootstrapped 95% confidence interval (CI). We also investigated the predictive role of GLS by fitting a multivariable linear model with LVEF at V4 as the outcome, with GLS at V1 and V2, LVEF at V1 and V2, age, sex, radiotherapy, hypertension, diabetes, smoking status, and dyslipidaemias as explanatory variables.
Inter-observer agreement and intra-observer agreement were assessed by the concordance correlation coefficient. Inter-observer agreement on decision of AIC was evaluated using the Kappa statistic.
All statistical analyses were performed using R version 3.1.2.
Results
Population
The patient flow chart is presented in Figure 1 . From November 2011 to April 2014, 111 patients were assessed for eligibility. Nineteen patients met the exclusion criteria, including 11 patients (10%) with poor echogenicity results, leaving a study population of 92 patients. Two patients died (one after V1 and the other after V3), two developed atrial fibrillation between V3 and V4, one was lost to followup by moving abroad, and one patient withdrew consent; the remaining 86 patients were included in the final analysis. Six patients (7%) developed AIC by 12-month follow-up. Patient baseline characteristics are summarized in 
Echocardiographic parameters of systolic and diastolic function
The echocardiographic variables measured at baseline (V1) and during follow-up (V2-V4) in patients with and without AIC are listed in Table 2 . Figures 2 and 3 , respectively, present box plots of GLS and LVEF at each visit. GLS at V2 was significantly lower in the AIC group vs. the non-AIC group (P ¼ 0.01) ( Table 2) . Similarly, GLS at V3 was significantly lower in the AIC group (P ¼ 0.00014). We also performed a subgroup analysis including patients with and without radiotherapy. Although baseline LVEF was significantly lower in the radiotherapy group (P ¼ 0.0148), there were no differences in GLS and LVEF at V2, V3, and V4 between patients who did or did not received radiation therapy ( Table 3) . Table 4 lists the change in the echocardiographic variables between V1 and V2. LVEF ( 
Multiple linear regression and predictors of anthracycline cardiotoxicity
Results of multiple regression are presented in Table 5 . GLS at V2 (P ¼ 0.011) and LVEF at V1 (P ¼ 0.016) were the only independent factors associated with LVEF at V4.
GLS at V1 and at V2 were both predictive of AIC. Based on the ROC curve ( Figure 4 and Table 6 ), GLS at V2 appears to be the strongest predictor of subsequent LVEF reduction at 1 year (area under the curve 0.82). At a threshold of -17.45% for GLS, the sensitivity and specificity to detect AIC were 67% (95% CI 33-100) and 97% (95% CI 94-100), respectively ( GLS at low-dose anthracycline-based chemotherapy 
Discussion
In this prospective cohort study, we demonstrate that GLS greater than -17.45%, obtained after 150 mg/m 2 of anthracycline therapy, is an independent predictor of future AIC in adults with lymphoma or leukaemia.
Incidence of AIC
Although the incidence of AIC in our study is consistent with the published literature, 15 it was lower than the rate in most papers addressing the usefulness of GLS as predictor of chemotherapy cardiotoxicity. This finding may be explained in part by the more restrictive but more specific definition of AIC than usually used. Before the publication of a recent consensus paper, 12 the most commonly used definition of cardiotoxicity was a !5% reduction in LVEF from baseline in symptomatic patients (or !10% in asymptomatic patients), to an LVEF <55%. 16, 17 This definition was used largely for trastuzumabinduced cardiotoxicity and, by extension, to characterize AIC. GLS at V1; GLS at V2; and abGLS, DGLS, and LVEF at V2 were evaluated to predict a decrease in LVEF by >10%, to a value <53% at 1 year. abGLS, absolute change in GLS between V1 and V2; DGLS, per cent change in GLS between V1 and V2; V, visit.
. 
Optimal variables to predict AIC
Our study confirms the value of systolic myocardial deformation variables (especially GLS, which appears to be the most robust measure) for the early prediction of cardiotoxicity in patients receiving anthracycline therapy. This finding is consistent with other studies, 23 where GLS (either absolute level or percentage reduction between two visits) is predictive of AIC. Table 8 summarizes the cut-off values found in previous studies addressing this issue. [8] [9] [10] 20, 22, [24] [25] [26] From this table, we can see that absolute levels of GLS greater than -19% at the completion of treatment, 8 and greater than -20.5% at 6 months, 10 are significant predictors of a subsequent decrease in LVEF. Because our threshold value obtained at V2 is not included within the normal range of GLS and maximizes specificity, we hope it will be relevant in daily clinical practice. Surprisingly, variations in GLS (abGLS and DGLS) at V2 were not predictive of cardiotoxicity. This finding is likely to be due to early echocardiographic evaluation.
Value of GLS at baseline
Interestingly, GLS measured at V1 was significantly lower in the AIC group than in the non-AIC group. This finding is supported by a recent study by Mousavi et al., 27 in which the baseline measurement of GLS was a strong predictor of major adverse cardiac events, defined as New York Heart Association class III or IV congestive heart failure, cardiac arrest, or cardiac death. Indeed, in the study by Mousavi et al., GLS greater than -16% was associated with a 4.7-fold increase in major adverse cardiac events. This alteration probably reflects 'pretherapy left ventricular dysfunction' and needs to be considered a risk factor for developing AIC.
Optimal timing to perform echocardiography
To our knowledge, our study is the first to address the optimal timing of performing the first echocardiography in the setting of anthracycline therapy. In most previous studies, echocardiography was performed at a definite time point after the beginning of treatment (usually at 3 or 6 months). Anthracycline treatment regimens vary among patients, however, and this strategy can lead to variation in the doses of anthracyclines delivered at the time of the first echocardiography. Thus, assuming the fact that the cumulative dose of anthracycline is a major predictor of cardiotoxicity, 7, 28 we chose a fixed dose of anthracycline therapy rather than a definite time from baseline.
Targeting a cumulative dose of 150 mg/m 2 for V2
In the setting of AIC, three different types of cardiotoxicities 29 (acute, early-onset chronic progressive, and late-onset chronic progressive) have been recognized. The acute form occurs immediately after anthracycline administration and leads to transient, and most of the time reversible, impairment of myocardial contractility. Indeed, Ganame et al. 30 have shown early impairment of strain variables (as early as 2 h after the first anthracycline dose), but we do not know whether this dysfunction reflects acute/beginning of chronic, reversible/irreversible injury of the heart and whether it is predictive of subsequent cardiotoxicity. For this reason, we did not perform V2 after a very low dose of anthracycline therapy (<75 mg/m 2 ), to avoid bias caused by the type of AIC studied. Moreover, Drafts et al.
11 suggest a rate of LVEF < 50% of 26% at 6 months of follow-up after therapy in patients who have received low doses of anthracyclines (<375 mg/ m 2 ). As a result, we believe the correct point at which to perform V2 needed to be included between 75 mg/m 2 (a dose that shows evidence of subclinical left ventricular function alteration) and 375 mg/ m 2 (before impairment of systolic function detected by ejection fraction). Given the lack of data between these two doses, we chose empirically 150 mg/m 2 for our second echocardiographic evaluation.
Population
It is remarkable that none of the patients who developed AIC had conventional cardiovascular risk factors (except for smoking) or radiotherapy associated with chemotherapy. This finding is probably due to the small sample size analysed and does not reflect real-life practice. Indeed, several studies support the influence of cardiovascular risk factors and radiotherapy as risk factors for developing AIC. 15, 31 It is important to note that none of the patients included in the analysis had beta-blocker or angiotensin-converting enzyme inhibitor treatment started between V1 and V4. For those who received these medications before V1, treatments were continued throughout the drugs (titrated dose of bisoprolol and enalapril) after V4. Of note, one patient exhibited a severe drop in GLS and ejection fraction between V2 and V3 followed by ad integrum recovery at V4. Because this patient experienced severe sepsis between V2 and V3, we concluded that the alteration of systolic function was related to sepsisinduced cardiac dysfunction rather than to AIC.
Limitations
As the number of patients who developed AIC was small, our findings need to be confirmed in a larger population. Thus, given the small sample size and low number of cardiotoxicity events, the threshold value derived from ROC curve analysis should be interpreted with caution. Furthermore, we cannot exclude the possibility that the inclusion of a greater number of patients could have led to the baseline GLS having greater power to predict future events. Radial and circumferential deformations were not taken into account, mainly because longitudinal strain is more reproducible and more relevant for clinical application. Because of the inter-vendor variability of GLS, we do not know whether our findings can be applied using another vendor than that used in the current study.
Conclusions
The results from this prospective study suggest that AIC may be predicted by early measures of GLS, i.e. at baseline and after administration of low doses of anthracyclines (150 mg/m 2 ). The findings emphasize the need for very early assessment of GLS in the time course of anthracycline therapy to detect cardiotoxicity. Alterations in GLS during anthracycline therapy identify a population at high risk for developing AIC. A cut-off value of GLS greater than -17.45% should encourage physicians to initiate cardioprotective treatment (such as beta-blockers and angiotensin-converting enzyme inhibitors) and to discuss a 'personalized' echocardiographic follow-up.
. ........................................................................................................................................................................................................................................................................................................ ..... N, number of patients; GE, General electric; HF, heart failure.
